Kartal Mehmet Oğuz, Kartal Ayşenur Sinem, Kurucu Burçak, Özyörük Derya, Şahin Gürses, Gülaldi Nedim C M
Department of Nuclear Medicine, University of Health Sciences, Ankara Bilkent City Hospital.
Department of Pediatric Hematology and Oncology, Etlik City Hospital.
Clin Nucl Med. 2025 Jul 1;50(7):e407-e416. doi: 10.1097/RLU.0000000000005874. Epub 2025 Mar 31.
18 F-FDG PET/CT plays a crucial role in the evaluation and management of pediatric classic Hodgkin lymphoma (cHL). In addition to visual assessment, quantitative parameters also have prognostic value. This study aimed to investigate the prognostic significance of PET parameters, with a particular focus on the changes observed in these parameters after 2 cycles of chemotherapy, in pediatric cHL patients.
The study was designed as a single-center, retrospective. A total of 198 pediatric cHL patients who underwent baseline and post-2-cycle chemotherapy interim 18 F-FDG PET/CT imaging between January 2019 and October 2023 were included in the study. Four different segmentation methods (%41 SUVmax, %42 SUVmax, mediastinal SUVmax, and liver SUVmax) were applied. Quantitative parameters, including metabolic tumor volume (MTV), total lesion glycolysis (TLG), and their changes after 2 chemotherapy cycles (ΔMTV, ΔTLG), were evaluated for each segmentation method. The prognostic significance of these parameters for progression-free survival (PFS) was assessed using Cox regression analysis, while survival differences based on optimal cutoff values were evaluated using Kaplan-Meier analysis.
A total of 48 pediatric cHL patients (32 males, median age: 12 y) met the inclusion criteria. During a median follow-up of 21 months (range: 5-52 mo), disease progression was observed in 22.9% of the patients (n=11). Baseline 18 F-FDG PET/CT quantitative parameters did not show significant differences between progression and nonprogression groups. However, on interim 18 F-FDG PET/CT, higher values of quantitative parameters from 3 segmentation methods (%41 SUVmax, %42 SUVmax, and mediastinal SUVmax) and lower postchemotherapy reductions in ΔSUVmax, ΔMTV (41) , ΔMTV (42) , ΔTLG (41) , and ΔTLG (med) were associated with poor PFS. In multivariate Cox regression analysis, i-SUVmax (Hazard ratio, HR: 1.20, P <0.001) and ΔMTV (41) (HR: 0.965, P =0.007) were identified as independent risk factors for PFS.
Interim 18 F-FDG PET parameters and postchemotherapy changes demonstrated significant prognostic value. Quantitative evaluation beyond visual assessment may contribute to risk-adapted and personalized treatment approaches in pediatric cHL.
18F-FDG PET/CT在儿童经典型霍奇金淋巴瘤(cHL)的评估和管理中起着关键作用。除了视觉评估外,定量参数也具有预后价值。本研究旨在探讨PET参数的预后意义,特别关注儿童cHL患者化疗2个周期后这些参数的变化。
本研究设计为单中心回顾性研究。纳入了2019年1月至2023年10月期间接受基线和化疗2个周期后的中期18F-FDG PET/CT成像的198例儿童cHL患者。应用了四种不同的分割方法(%41 SUVmax、%42 SUVmax、纵隔SUVmax和肝脏SUVmax)。对每种分割方法评估了包括代谢肿瘤体积(MTV)、总病变糖酵解(TLG)及其化疗2个周期后的变化(ΔMTV、ΔTLG)等定量参数。使用Cox回归分析评估这些参数对无进展生存期(PFS)的预后意义,同时使用Kaplan-Meier分析评估基于最佳临界值的生存差异。
共有48例儿童cHL患者(32例男性,中位年龄:12岁)符合纳入标准。在中位随访21个月(范围:5 - 52个月)期间,22.9%的患者(n = 11)出现疾病进展。基线18F-FDG PET/CT定量参数在进展组和非进展组之间未显示出显著差异。然而,在中期18F-FDG PET/CT上,三种分割方法(%41 SUVmax、%42 SUVmax和纵隔SUVmax)的定量参数值较高,以及化疗后ΔSUVmax、ΔMTV(41)、ΔMTV(42)、ΔTLG(41)和ΔTLG(med)的降低幅度较小与不良PFS相关。在多变量Cox回归分析中,i-SUVmax(风险比,HR:1.20,P <0.001)和ΔMTV(41)(HR:0.965,P = 0.007)被确定为PFS的独立危险因素。
中期18F-FDG PET参数和化疗后变化显示出显著的预后价值。视觉评估之外的定量评估可能有助于儿童cHL的风险适应性和个性化治疗方法。